Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Outset Medical, Inc. (OM)

Outset Medical Q2 revenue rises 1% to $31.6 million; net loss narrows

Positive Impact 3 of 5 earnings Written later

Outset Medical reported second quarter 2026 revenue of $31.6 million, up 1% from a year earlier, and a net loss of $18.0 million, or $0.97 per share, versus $18.5 million, or $1.04 per share, in the prior-year quarter. The company reiterated its 2026 revenue guidance of $125 million to $130 million, but product revenue and recurring revenue both declined from the prior year.

Key points

  • Revenue of $31.6 million rose 1% from $31.4 million; product revenue fell 5% to $21.9 million and service and other revenue rose 17% to $9.7 million.
  • Gross margin was 42.0% versus 37.8% a year earlier; net loss was $18.0 million, or $0.97 per share, versus $18.5 million, or $1.04 per share.
  • 2026 revenue guidance of $125 million to $130 million was reiterated, and non-GAAP gross margin is expected in the low-40% to mid-40% range for the full year.
  • The company signed a three-year, $40 million agreement with HCA Healthcare to refresh its Tablo systems; cash and investments totaled $151.0 million at June 30, 2026.

The filing

CompanyOutset Medical, Inc. (OM)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:05 PM ET
Accession number0001193125-26-337953

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.